Inventiva (IVA) Net Income towards Common Stockholders (2019 - 2021)
Inventiva (IVA) recorded quarterly Net Income towards Common Stockholders of -$10.2 million in Q2 2021, down 34.44% quarter-over-quarter from -$7.6 million in Q1 2021, and down 5.72% on a YoY basis from -$10.9 million in Q2 2020.
Inventiva (IVA) Net Income towards Common Stockholders (2019 - 2021) Analysis & Trends
Inventiva's Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$10.2 million for Q2 2021.
- In Q2 2021, Net Income towards Common Stockholders fell 5.72% year-over-year to -$10.2 million; the TTM figure through Sep 2022 stood at -$10.2 million (changed N/A YoY), while the FY2025 annual figure was -$198.4 million, down 0.95% from the prior year.
- Net Income towards Common Stockholders was -$10.2 million for Q2 2021 at Inventiva, down from -$7.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$7.5 million in Q1 2020 to a low of -$35.5 million in Q4 2020.
- Historically, Net Income towards Common Stockholders has averaged -$17.3 million across 3 years, with a median of -$10.0 million in 2020.
- The sharpest annual moves came in 2020 and 2021: Net Income towards Common Stockholders decreased 6.2% in 2020, then fell 1.78% in 2021.
- A 3-year view of Net Income towards Common Stockholders shows it stood at -$33.4 million in 2019, then retreated by 6.2% to -$35.5 million in 2020, then jumped by 71.15% to -$10.2 million in 2021.
- The last three Net Income towards Common Stockholders figures came in at -$10.2 million (Q2 2021), -$7.6 million (Q1 2021), and -$35.5 million (Q4 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -56.48 Mn |
| 10 | Inventiva | 8.52 Mn | -260.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -10.23 Mn |
| Mar 31, 2021 | -7.61 Mn |
| Dec 31, 2020 | -35.45 Mn |
| Jun 30, 2020 | -9.68 Mn |
| Mar 31, 2020 | -7.48 Mn |
| Dec 31, 2019 | -33.38 Mn |